Activating and inhibitory receptors on synovial fluid natural killer cells of arthritis patients: Role of CD94/NKG2A in control of cytokine secretion

Immunology

Volumn 122, Issue 2, 2007, Pages 291-301

  De Matos, Cristina Teixeira ^a   Berg, Louise ^a   Michaëlsson, Jakob ^a,b   Felländer Tsai, Li ^b   Kärre, Klas ^a   Söderström, Kalle ^c  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c STANFORD UNIVERSITY   (United States)

Author keywords

Autoimmunity; Cell surface molecules; Cytokines; Inflammation; Natural killer cells

Indexed keywords

CD69 ANTIGEN; GAMMA INTERFERON; HLA A ANTIGEN; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR;

ADULT; AGED; ARTHRITIS; ARTICLE; AUTOIMMUNITY; BEHCET DISEASE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; FLOW CYTOMETRY; HUMAN; IMMUNE RESPONSE; JUVENILE RHEUMATOID ARTHRITIS; MAJOR CLINICAL STUDY; MIXED CONNECTIVE TISSUE DISEASE; NATURAL KILLER CELL; PHENOTYPE; POLYARTHRITIS; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; REACTIVE ARTHRITIS; SYNOVIAL FLUID;

ADULT; AGED; ANTIGENS, CD94; CELLS, CULTURED; COCULTURE TECHNIQUES; CYTOKINES; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA ANTIGENS; HUMANS; IMMUNOPHENOTYPING; KILLER CELLS, NATURAL; KNEE INJURIES; KNEE JOINT; MIDDLE AGED; OSTEOARTHRITIS, KNEE; RECEPTORS, IMMUNOLOGIC; SYNOVIAL FLUID;

EID: 34548597175     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/j.1365-2567.2007.02638.x     Document Type: Article

References (28)

1. Firestein GS, Zvaifler NJ. How important are T cells in chronic rheumatoid synovitis? II. T cell-independent mechanisms from beginning to end. Arthritis Rheum 2002 46 : 298 308.
2. Edwards JC, Leandro MJ, Cambridge G. B lymphocyte depletion therapy with rituximab in rheumatoid arthritis. Rheum Dis Clin North Am 2004 30 : 393 403, viii.
3. Malmstrom V, Trollmo C, Klareskog L. The additive role of innate and adaptive immunity in the development of arthritis. Am J Med Sci 2004 327 : 196 201.
4. Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 1996 14 : 397 440.
5. Muller-Ladner U, Gay RE, Gay S. Activation of synoviocytes. Curr Opin Rheumatol 2000 12 : 186 94.
6. Dalbeth N, Callan MF. A subset of natural killer cells is greatly expanded within inflamed joints. Arthritis Rheum 2002 46 : 1763 72.
7. negative phenotype. Rheumatology (Oxford) 2003 42 : 870 8.
8. bright NK cells are enriched at inflammatory sites and can engage with monocytes in a reciprocal program of activation. J Immunol 2004 173 : 6418 26.
9. Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. Trends Immunol 2001 22 : 633 40.
10. dim NK cells. Eur J Immunol 2001 31 : 3121 7.
11. - natural killer cells is selectively responsible for both cell proliferation and interferon-gamma production upon interaction with dendritic cells. Eur J Immunol 2004 34 : 1715 22.
12. Kim CH, Pelus LM, Appelbaum E, Johanson K, Anzai N, Broxmeyer HE. CCR7 ligands, SLC/6Ckine/Exodus2/TCA4 and CKbeta-11/MIP-3beta/ELC, are chemoattractants for CD56(+) CD16(-) NK cells and late stage lymphoid progenitors. Cell Immunol 1999 193 : 226 35.
13. bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2. A potential new link between adaptive and innate immunity. Blood 2003 101 : 3052 7.
14. Ferlazzo G, Thomas D, Lin SL, Goodman K, Morandi B, Muller WA, Moretta A, Munz C. The abundant NK cells in human secondary lymphoid tissues require activation to express killer cell Ig-like receptors and become cytolytic. J Immunol 2004 172 : 1455 62.
15. bright cells in tuberculous pleurisy. J Immunol 2005 175 : 6852 60.
16. + T-cells in sarcoidosis patients. Eur Respir J 2005 26 : 77 85.
17. Moretta A, Bottino C, Vitale M, Pende D, Cantoni C, Mingari MC, Biassoni R, Moretta L. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol 2001 19 : 197 223.
18. Braud VM, Allan DS, O'Callaghan CA et al. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature 1998 391 (6669 795 9.
19. Lanier LL, Corliss B, Wu J, Phillips JH. Association of DAP12 with activating CD94/NKG2C NK cell receptors. Immunity 1998 8 : 693 701.
20. De Maria A, Fogli M, Costa P, Murdaca G, Puppo F, Mavilio D, Moretta A, Moretta L. The impaired NK cell cytolytic function in viremic HIV-1 infection is associated with a reduced surface expression of natural cytotoxicity receptors (NKp46, NKp30 and NKp44). Eur J Immunol 2003 33 : 2410 8.
21. Hendrich C, Kuipers JG, Kolanus W, Hammer M, Schmidt RE. Activation of CD16+ effector cells by rheumatoid factor complex. Role of natural killer cells in rheumatoid arthritis. Arthritis Rheum 1991 34 : 423 31.
22. Cooper MA, Fehniger TA, Turner SC, Chen KS, Ghaheri BA, Ghayur T, Carson WE, Caligiuri MA. Human natural killer cells. A unique innate immunoregulatory role for the CD56 (bright) subset. Blood 2001 97 : 3146 51.
23. Michaelsson J, Teixeira de Matos C, Achour A, Lanier LL, Karre K, Soderstrom K. A signal peptide derived from hsp60 binds HLA-E and interferes with CD94/NKG2A recognition. J Exp Med 2002 196 : 1403 14.
24. Ferlazzo G, Pack M, Thomas D et al. Distinct roles of IL-12 and IL-15 in human natural killer cell activation by dendritic cells from secondary lymphoid organs. Proc Natl Acad Sci USA 2004 101 : 16606 11.
25. Nagler A, Lanier LL, Cwirla S, Phillips JH. Comparative studies of human FcRIII-positive and negative natural killer cells. J Immunol 1989 143 : 3183 91.
26. Nagler A, Lanier LL, Phillips JH. Constitutive expression of high affinity interleukin 2 receptors on human CD16-natural killer cells in vivo. J Exp Med 1990 171 : 1527 33.
27. Raza K, Falciani F, Curnow SJ et al. Early rheumatoid arthritis is characterized by a distinct and transient synovial fluid cytokine profile of T cell and stromal cell origin. Arthritis Res Ther 2005 7 : R784 95.
28. Karlsson-Parra A, Soderstrom K, Ferm M, Ivanyi J, Kiessling R, Klareskog L. Presence of human 65 kD heat shock protein (hsp) in inflamed joints and subcutaneous nodules of RA patients. Scand J Immunol 1990 31 : 283 8.